Bottom line
XLV vs SCHLX: the short answer
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and SCHLX (DWS Health and Wellness Fund) share a meaningful slice of their top holdings — about 81% by weight.
XLV is cheaper at 0.08% vs 1.06% — a difference of $98 a year per $10,000 invested.
Updated Nov 19, 2026
XLV vs SCHLX side by side
| XLV | SCHLX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | SPDR (State Street) | DWS (Xtrackers) |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.08% | 1.06% |
| Annual cost per $10k | $8 | $106 |
| 10-yr cost on $10k (prospectus) | $103 | $1,294 |
| Max front load | None | 0% |
| 12b-1 fee | 0.02% | 0% |
| 1-yr return | +14.5% | — |
| 5-yr return (annualized) | +8.1% | — |
| 10-yr return (annualized) | +9.8% | — |
| Best quarter | +14.5% | — |
| Worst quarter | −12.7% | — |
| Net assets (fund) | $40.6B | $231.8M |
| Number of holdings | 65 | 65 |
| Portfolio turnover | 2% | 2% |
| Returns as of | Dec 31, 2025 | — |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
21 of XLV's top 25 holdings also appear in SCHLX's top 25.
| Holding | XLV | SCHLX |
|---|---|---|
| Eli Lilly & Co | 16.51% | 13.85% |
| Johnson & Johnson | 10.64% | 6.19% |
| AbbVie Inc | 7.74% | 4.90% |
| UnitedHealth Group Inc | 6.57% | 5.73% |
| Merck & Co Inc | 5.52% | 4.85% |
| Amgen Inc | 3.40% | 2.88% |
| Thermo Fisher Scientific Inc | 3.24% | 3.46% |
| Abbott Laboratories | 2.75% | 2.39% |
| Gilead Sciences Inc | 2.73% | 2.78% |
| Intuitive Surgical Inc | 2.45% | 2.69% |
| Pfizer Inc | 2.39% | 1.17% |
| Vertex Pharmaceuticals Inc | 2.19% | 2.45% |
| Danaher Corp | 2.09% | 2.13% |
| Bristol-Myers Squibb Co | 2.05% | 1.50% |
| Stryker Corp | 1.89% | 2.61% |
Source: SEC Form N-PORT
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
SCHLX top 10
- Eli Lilly & Co — 13.85%
- Johnson & Johnson — 6.19%
- UnitedHealth Group Inc — 5.73%
- AbbVie Inc — 4.90%
- Merck & Co Inc — 4.85%
- AstraZeneca PLC — 3.80%
- Thermo Fisher Scientific Inc — 3.46%
- Novartis AG — 2.90%
- Amgen Inc — 2.88%
- Gilead Sciences Inc — 2.78%
FAQ
What is the difference between XLV and SCHLX?
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and SCHLX (DWS Health and Wellness Fund) share a meaningful slice of their top holdings — about 81% by weight. XLV is cheaper at 0.08% vs 1.06% — a difference of $98 a year per $10,000 invested.
Which is cheaper, XLV or SCHLX?
XLV has the lower expense ratio (0.08%).
Should I own both XLV and SCHLX?
Owning both adds little diversification because their portfolios overlap heavily; most investors pick one.
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.